Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transcriptional activation of eukaryotic genes involves assembly of specific multiprotein complexes on the promoters and enhancers of the genes. Recently, it has been proposed that the role of some of the proteins in the complex may be architectural, involving DNA bending, orchestration of protein-protein interaction and modulation of nucleosome structure. This role has been proposed for the HMG proteins
LEF-1
and TCF-1. We examined the role of a
LEF-1
/TCF-1 binding site in the human
adenosine deaminase
(
ADA
) thymic enhancer. Mutational analysis demonstrated that a functional
LEF-1
/TCF-1 binding site is not required for enhancer-mediated transcriptional activation in transient transfection studies, but is essential for enhancer function in the in vivo chromatin context of transgenic mice. Mutation of the
LEF-1
/TCF-1 site destroyed the ability of the
ADA
enhancer/locus control region to specify high level, insertion site-independent transgene expression in thymus. DNase I and DpnII accessibility experiments indicated dramatic changes in the chromatin organization of the
ADA
enhancer in transgenic mice with a mutated
LEF-1
/TCF-1 site. This supports the hypothesis that factors binding the
LEF-1
/TCF-1 site play an architectural role during the in vivo activation of the
ADA
enhancer, possibly involving chromatin modification.
...
PMID:An enhancer LEF-1/TCF-1 site is essential for insertion site-independent transgene expression in thymus. 901 77